Osseon receives second patent NOA for spinal vertebral compression fracture technology

Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, received its second patent Notice of Allowance (NOA) for its spinal vertebral compression fracture (VCF) technology.  The company, which was started in 2006, now has two allowed and twelve additional patent applications pending in the United States, and several others throughout the world for spinal therapies and devices.  

The company has been marketing its FDA and CE Mark cleared "Osseoplasty™" system in the U.S. and Europe, since February, 2009 and February, 2010, respectively.  The proprietary Osseoplasty™ procedure has been performed in over 1,100 patients in the U.S. and Europe.

According to John Stalcup, Ph.D., President and CEO of Osseon, "This second patent allowance for Osseon's spinal VCF technology is another cornerstone for the company's intellectual property foundation.  We continue to strengthen our intellectual property position and strive to obtain additional patents in the future on various aspects of the Osseoflex® steerable and curvable needle and the novel methods for bone cement delivery, which enable a safe, effective, and minimally invasive approach for spine disease treatment."